



## **Cancer Immunotherapy: Precision Diagnosis** and Personalized Medicine

Dr. Jan Mou Lee

FullHope Biomedical Co., Ltd. Founder and General Manager

In recent years, immunotherapy has emerged as a new trend in cancer treatment, including precision diagnosis and personalized treatment. One such development by Fuhwa Biotech is a precision diagnostic system that includes immune function analysis (IP) and circulating tumor cell analysis (CTC).

Immune function analysis can assess the likelihood of disease onset at an early stage, including cancer and other immune-related diseases. For individuals who feel abnormally fatigued in daily life or experience unexplained chronic fatigue, immune function analysis can provide recommendations to improve quality of life. After conducting immune function analysis for cancer patients, doctors can use the data to determine suitable treatments, such as immune checkpoint inhibitors (ICI) or adoptive cell therapy (ACT), for personalized therapy.

Circulating tumor cell analysis can be used for early cancer risk assessment, allowing for the detection of cancer in its early stages or even before recurrence, enabling timely treatment and achieving early screening and early treatment benefits. This analysis can also be used during cancer treatment to monitor tumor cell metastasis, providing real-time information to both physicians and patients. By combining this with targeted therapy analysis, it can evaluate how targeted drugs affect cancer treatment. When combined with AI interpretation tools, the system can precisely analyze different types of cells, generate large amounts of data, and assist in analysis and decision-making.

